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Abstract
In recent years, the pathogenic role of human immunodeﬁciency virus (HIV) and the clinical manifestations of HIV-associated pulmonary
arterial hypertension (HIV-PAH), which currently represents one of the most severe complications of HIV infection, have received more
attention HIV-PAH occurs at all stages of the disease, and does not seem to be related to the degree of immune deﬁciency. Many of
the symptoms in HIV-PAH result from right ventricular dysfunction: the ﬁrst clinical manifestation is effort intolerance and exertional
dyspnoea that will progress to the point of breathlessness at rest. Echocardiography is an extremely useful tool for the diagnosis of
HIV-PAH, and Doppler echocardiography can be used to estimate systolic pulmonary artery pressure. Assessment of haemodynamic
measures by catheterization remains, however, the best test for evaluating the response to therapy. Cardiac catheterization is man-
datory to deﬁnitively diagnose the disease and exclude any underlying cardiac shunt as the aetiology. Recently, effective therapies for
pulmonary arterial hypertension (PAH) have been available, including prostanoids, endothelin receptor antagonists, and phosphodiester-
ase-5 inhibitors, allowing amelioration of symptoms and a better prognosis. However, HIV-PAH remains a progressive disease for which
treatment is often unsatisfactory and there is no cure. As new efﬁcient antiretroviral treatment is introduced, clinicians should expect
to encounter an increasing number of cases of PAH in HIV-infected patients in the future.
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Introduction
Although the introduction of highly active antiretroviral ther-
apy (HAART) 15 years ago transformed human immunodeﬁ-
ciency virus (HIV) infection into a chronic infectious disease,
HIV remains an intractable pathogen at the clinical and basic
science levels worldwide.
While the search for a cure continues, long-term cardio-
vascular complications of HIV infection have now become
signiﬁcant contributors to morbidity and mortality. Pulmo-
nary arterial hypertension (PAH) was probably undetected
before the advent of HAART, because patients succumbed
to immunodeﬁciency and opportunistic infections. PAH
results from chronic obstruction of small pulmonary arteries,
leading to right ventricular failure, and death. HIV infection is
one established risk factor for PAH [1–3].
The ﬁrst case of PAH in an HIV-infected subject was
described in 1987 [4]. Recently, more attention has been
paid to the pathogenic role of HIV and the clinical manifesta-
tions of HIV-associated PAH (HIV-PAH) [5–7], one of the
most severe complications of HIV disease.
Epidemiology of PAH in HIV-infected
Patients
In 1991, the prevalence of HIV-PAH in developed countries
was estimated to be 0.5% [8]; this prevalence remains the
same [5,6,9,10] regardless of HAART.
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However, the actual prevalence of HIV-PAH could be
higher, as most published studies evaluating HIV-PAH are
not able to include the asymptomatic patients [11].
Furthermore, the epidemiology of HIV-PAH could be dif-
ferent in developing countries. For example, in an echocar-
diographic study conducted in Burkina Faso (West Africa),
the prevalence of pulmonary hypertension (PH) was found
to be 5% [12].
Nevertheless, data from the Swiss HIV Cohort Study
showed that the incidence of newly diagnosed cases of PAH
in HIV-infected patients decreased from 0.24% in 1993 to
0.03% in 2006 [5,9]. This decrease was related to changes in
modes of HIV infection transmission, HAART-induced
increases in CD4 cell counts, and a decrease in immune acti-
vation [5].
The average age of HIV-PAH patients is 33 years [13].
The male/female ratio is about 1.5 : 1 [3,13–15]. This ratio is
different from that of uninfected patients with idiopathic
PAH, in whom the female/male ratio is 1.7 : 1. This ﬁnding
may reﬂect the higher frequency of HIV infection among
male patients. More recently, however, a slightly marked
female predominance in HIV-PAH patients has been sug-
gested [11].
HIV-PAH occurs at all stages of HIV infection, and does
not seem to be related to the immune deﬁciency [14]. No
speciﬁc risk factors for HIV infection are associated with this
disease, although HIV-PAH is more frequent in intravenous
drug users, who represented 59% of cases of HIV-PAH in a
French cohort study [15]. However, patients with HIV-PAH
acquired via intravenous drug use have no clinical, functional
or haemodynamic differences from patients with HIV-PAH
acquired via another transmission route [7]. The role of
intravenous drug use as an independent risk factor for PAH
was recently ruled out [2]. The presence of PAH is an inde-
pendent risk factor for mortality in patients with HIV infec-
tion, and, in most cases, death is causally related to PAH
rather than to other complications of HIV infection [14,15].
In a study by Opravil et al. [1], the median survival of HIV-
PAH patients was signiﬁcantly lower than that of HIV-
infected patients without PAH (1.3 vs. 2.6 years, respectively;
p <0.05). These data reﬂect the independent contribution of
PAH to mortality in HIV-infected patients, because only a
small proportion of patients were treated with antiretrovirals
(zidovudine or didanosine only) and no patients received
PAH-speciﬁc therapy.
Data on the characteristics and outcomes of patients with
PAH-HIV in the current era of HAART and speciﬁc PAH
therapies are scanty. In the Swiss HIV Cohort Study, the
median survival period for 66 patients with HIV-PAH (43 of
66 patients on HAART) was 3.6 years, with 84% surviving
to 1 year [5]. The prognosis is particularly poor for patients
in NYHA functional class III–IV, with a 3-year survival rate
of only 28% [15]. A recent study of 77 HIV-PAH patients
from the French Reference Centre for PAH (most patients
on HAART at PAH diagnosis and 50 of 77 patients on PAH-
speciﬁc therapy) showed overall survival rates of 88%
and 72% at 1 and 3 years, respectively [7]. A cardiac index
of >2.8 L/m per m2 and a CD4 T-lymphocyte count of
>200 cell/mm3 were the only independent predictors of
increased survival [7].
Clinical Presentation
Most symptoms of HIV-PAH result from right ventricular
dysfunction. As the predominant symptom is progressive
shortness of breath, which can be present in many other
clinical manifestations, the disease is typically diagnosed late
in its course, when the clinical and laboratory ﬁndings of
severe PH are generally present.
In a review of 131 cases of HIV-PAH, Mehta et al. [13]
found that progressive shortness of breath was the most
common presenting symptom (85% of cases), followed by
pedal oedema (30%), non-productive cough (19%), fatigue
(13%), syncope or near syncope (12%), and chest pain (7%).
Usually, about 6 months elapse between the onset of
symptoms and the diagnosis of HIV-PAH [13]. This period is
shorter than that seen in idiopathic PAH, in which this per-
iod is, on average, 2.5 years [15]. One likely explanation for
this difference is the fact that HIV-infected patients are more
closely followed up, starting soon after initial HIV diagnosis.
However, a more aggressive type of PAH in HIV-infected
patients could not be ruled out.
Diagnosis
The diagnosis of PAH in HIV-infected patients requires a
sequential approach that, in practice, includes four steps: the
clinical suspicion of PH, the detection of PH, the exclusion of
other possible causes of PH, and the PAH evaluation (Fig. 1).
Clinical suspicion of PH
The clinical suspicion of PH should arise in any case of breath-
lessness without overt signs of heart-speciﬁc or lung-speciﬁc
disease or in patients with underlying cardiopulmonary disease
whenever there is increasing dyspnoea unexplained by the
underlying disease itself.
The physical examination may reveal increased intensity of
pulmonic second heart sound (P2), with P2 louder than aortic
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second heart sound, right-sided third and fourth heart sound
gallop, murmurs of tricuspid and pulmonic regurgitation,
increased jugular venous pressure, and peripheral oedema
[13], and may also provide clues as to the cause of PH (e.g.
the stigmata of liver disease, such as spider naevi and palmar
erythema, in liver cirrhosis and portal hypertension).
Detection of PH
The detection of PH requires investigations that are able
to conﬁrm the diagnosis of PH, and includes the electro-
cardiogram, chest X-ray, and transthoracic Doppler echocar-
diography.
The ECG usually reveals right axis deviation, right ventric-
ular hypertrophy, and right atrial abnormalities [13]. Com-
plete and incomplete right bundle branch block may be
present.
As electrocardiography has insufﬁcient sensitivity (55%)
and speciﬁcity (70%) [16], it should be not considered to be
a screening tool for the detection of signiﬁcant PH. Indeed, a
normal electrocardiogram does not exclude the presence of
severe PH.
Chest X-ray generally shows enlarged central pulmonary
arteries and clear lung ﬁelds. Moreover, it helps to exclude
some causes of PH, such as chronic obstructive pulmonary
diseases and interstitial lung diseases. However, chest X-ray
cannot detect early changes in pulmonary arteries.
Transthoracic Doppler echocardiography is an extremely
useful tool for the diagnosis of HIV-PAH [16]; moreover, it
is extremely helpful in ruling out congenital, valvular and
myocardial disease.
The most frequent echocardiographic features are systolic
ﬂattening of the interventricular septum, enlargement of both
the right atrium and ventricle, and a reduction in both left
ventricular systolic and diastolic dimensions. Pericardial effu-
sion and patent foramen ovale are also frequently detected
[13].
Doppler echocardiography may be used to estimate sys-
tolic pulmonary arterial pressure (PAP) on the basis of the
peak velocity of the tricuspid valve regurgitant jet [16]. How-
ever, the false-positive rate from Doppler echocardiography
for PAH diagnosis in HIV-infected patients has been recently
reported to be as high as 72% [6].
Exclusion of other causes of PH
The next step to the diagnosis of HIV-PAH is the exclusion
of other possible causes of PH, as shown in Fig. 1.
PAH evaluation
Assessment of haemodynamic measures by right heart cathe-
terization remains the reference standard for diagnosing
HIV-PAH, as well as for assessing its severity and response
to therapy. PAH is deﬁned by a mean PAP (mPAP)
‡25 mmHg with a mean pulmonary capillary wedge pressure
£15 mmHg, and a normal or reduced cardiac output [16].
Acute vasodilator testing is an important component of
the haemodynamic assessment, as the response to acute
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FIG. 1. Human immunodeﬁciency virus-associated pulmonary hypertension diagnostic approach. PH, pulmonary hypertension; ECG, electrocar-
diogram; TTE, transthoracic echocardiography; ABG, arterial blood gas; CT, computed tomography; COPD, chronic obstructive pulmonary dis-
ease; PPH, portopulmonary hypertension; PAH, pulmonary arterial hypertension; 6MWD, 6-minute walking distance.
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challenge with vasodilators (e.g. inhaled nitric oxide or
intravenous epoprostenol or adenosine) is predictive of the
long-term response to oral therapy with calcium channel
blockers (CCBs).
A positive response is deﬁned as decrease of ‡10 mmHg
in mPAP, to reach an absolute mPAP value of £40 mmHg,
with either unchanged or increased cardiac output [16]. In
HIV-PAH, however, acute vasodilator testing rarely has a
positive response [17].
Exercise tolerance in PAH is commonly assessed by means
of the 6-minute walking distance (6MWD). Although the test
is not sufﬁciently validated in HIV-PAH, it is predictive of
survival in idiopathic PAH, and correlates inversely with
NYHA functional status severity [16]. Moreover, it repre-
sents an entry criterion and primary endpoint of many clinical
trials of therapeutic agents for PAH [16].
Treatment
Guidelines are not currently available for PAH therapy in
HIV-PAH, and no study has yet established a single agent of
choice for the treatment of HIV-PAH. Therefore, treatment
of HIV-PAH relies on PAH-speciﬁc therapy, and includes
supportive treatments and disease-speciﬁc treatments.
The therapeutic options for HIV-PAH are not well estab-
lished in comparison with other forms of PAH [16], and
there are still conﬂicting data on the role of HAART in the
management of patients with HIV-PAH.
Supportive therapy
Supportive therapy includes oxygen administration, diuretics,
digoxin and oral anticoagulants. Supplemental oxygen therapy
may beneﬁt patients who are hypoxic. Most experts recom-
mend oxygen supplementation when arterial blood oxygen
pressure is consistently £60 mmHg [16].
Patients with overt right ventricular failure should be trea-
ted with diuretics, which reduce right ventricular pre-load
[16]. Digoxin has been shown to improve cardiac output
acutely in patients with right ventricular dysfunction attribut-
able to PH [18]. However, the role of cardiac glycosides in
treating isolated right heart dysfunction is controversial.
These agents are most useful in cor pulmonale, when left
ventricular failure is also present. However, as neurohor-
monal sympathetic activation has been demonstrated in PH,
digoxin may be of value because of its sympatholytic proper-
ties [19].
Most experts recommend long-term anticoagulant therapy
with warfarin in patients with PAH. The rationale for anti-
coagulant therapy is based on the identiﬁcation of in situ
thrombosis of the small arterioles on post-mortem examina-
tion in patients with idiopathic PAH [20]. However, no data
actually support anticoagulant therapy speciﬁcally in patients
with PAH. In a systematic review of studies evaluating the
effectiveness of anticoagulant therapy in improving the
survival of patients with idiopathic PAH, ﬁve observational
studies were found to suggest a survival beneﬁt associated
with warfarin [21]. On the basis of these limited studies, a
target International Normalized Ratio between 1.5 and 2.5 is
recommended.
There is not enough supporting evidence for the use of
anticoagulants in HIV-PAH, although in situ thrombosis is
occasionally found. Increased risk of bleeding, also in relation
to frequently associated hepatic disease, anticipated com-
pliance issues, and drug–drug interactions, should be also
considered.
Speciﬁc therapy
CCBs. Recent data suggest that a long-term response to
CCBs may be present in HIV-PAH, although less frequently
than in other forms of PAH [7]. However, it is essential
to identify the responders by acute pulmonary vasodilator
testing before long-term CCB therapy is undertaken [7].
Moreover, the potential for drug–drug interactions should be
considered, especially for patients receiving antiretroviral
therapy with protease inhibitors (PIs) [22].
Prostanoids. The beneﬁcial effects of epoprostenol have been
demonstrated in patients with HIV-PAH, with a signiﬁcant
long-term decrease in mPAP and pulmonary vascular resis-
tance, and a signiﬁcant increase in mean cardiac output [23].
However, concern exists about the long-term use of
epoprostenol, which requires a permanent central venous
catheter for continuous infusion, adding the risk of infectious
complications, which is particularly important in HIV-infected
patients who are immune compromised [23,24].
Subcutaneous administration or nebulized prostacyclin
analogues may overcome the limitations of intravenous
administration, but there are few data regarding the use of
these compounds in HIV-PAH patients [25,26]. Subcutaneous
treprostinil enhanced functional parameters in three patients
with HIV-PAH [26]. Inhaled iloprost improved NYHA func-
tional capacity and 6MWD in four patients with severe HIV-
PAH, although the effect was not statistically signiﬁcant [25].
Endothelin receptor antagonists. Bosentan is an oral, non-selec-
tive endothelin-1 receptor antagonist that has been shown to
considerably improve all clinical and haemodynamic parame-
ters in PAH, and also in patients with HIV-PAH and NYHA
class III–IV [27]. In particular, signiﬁcant improvements were
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observed in 6MWD, cardiac index, pulmonary vascular
resistance, and right atrial area and eccentricity index at echo-
cardiography, all of which are considered to be prognostic
indicators for survival in patients with idiopathic PAH. A
recent retrospective study conﬁrmed the long-term beneﬁt of
bosentan therapy in HIV-PAH patients without impacting on
the control of HIV infection [28].
The newer selective endothelin A receptor antagonists
sitaxsentan and ambrisentan have been investigated for the
treatment of PAH, and have demonstrated improvements in
exercise tolerance and haemodynamics [16]; however, only a
single case of an HIV-PAH patient switching from bosentan
to sitaxsentan has been reported so far [29].
Phosphodiesterase-5 inhibitors. No controlled trials of the
phosphodiesterase-5 inhibitor sildenaﬁl in HIV-PAH currently
exist, and data on its beneﬁcial effects in HIV-PAH patients
derive from case studies, which have reported improvements
in dyspnoea and functional class [30–32].
Moreover, caution should be used in HIV-infected patients
receiving a HAART regimen containing PIs, as saquinavir and,
particularly, ritonavir have been shown to signiﬁcantly modify
the pharmacokinetics of sildenaﬁl, resulting in increased
plasma concentrations of both drug and metabolite [33].
Antiretroviral therapy
There is no current objective trial evaluating the still contro-
versial effect of HAART on the progression of HIV-PAH.
Recent data [5,7] suggested that HAART does not prevent
the development of PAH in HIV-infected patients, as most of
patients from these studies were receiving HAART at the time
of diagnosis of PAH. However, HAART could delay or attenu-
ate the development of PAH in HIV-infected patients [7].
Since the ﬁrst studies on HIV-PAH, the initiation of anti-
retroviral therapy has been recommended in all HIV-PAH
patients, irrespective of their CD4+ T-lymphocyte counts, on
the basis of improvements in pressure gradient over time in
HIV-PAH patients receiving zidovudine or didanosine as
compared with an increased gradient in untreated HIV-PAH
patients [1].
A study of 47 patients with HIV-PAH within the Swiss
Cohort Study found that patients receiving HAART had a
signiﬁcantly decreased median right ventricular systolic pres-
sure over right atrial pressure gradient ()21 mmHg) as com-
pared with patients who did not receive antiretroviral
therapy (+25 mmHg) [9]; moreover, HAART signiﬁcantly
reduced the risk of death in patients with HIV-PAH (hazard
ratio 0.075; 95% CI 0.02–0.28; p <0.001) [9], suggesting a
beneﬁcial effect of HAART in patients with HIV-PAH. By
contrast, two patients with HIV-PAH who were treated with
a PI-including HAART regimen experienced an accelerated
course of PAH, with worsening systolic PAP [34].
In a retrospective study of 82 patients, those in NYHA
functional class III–IV treated with epoprostenol plus HAART
had better survival than those receiving conventional therapy
plus HAART, suggesting that HAART alone does not
inﬂuence the progression of PAH [15]. An analysis of the
HIV-PAH cases reported in the literature (January 1987 to
January 2009) showed a more favourable outcome in
patients treated with PAH-speciﬁc therapy than in those
treated with antiretroviral therapy only [35].
More recently, long-term HAART without PAH-speciﬁc
therapy improved 6MWD, but not the haemodynamic
parameters, in most patients [7].
New Pathogenetic Insights into HIV-PAH
Infectious pathogens in the lung are known inducers of
vasculitis; whether this is a consequence of persistent viral
infection, exposure to toxic viral proteins or viral-induced
immune activation remain unknown. There is a signiﬁcant
evidence for vascular involvement in HIV/simian immunodeﬁ-
ciency virus infection, including arteriopathy with severe inti-
mal and smooth muscle hyperplasia in AIDS patients and in
simian immunodeﬁciency virus-infected macaques. As in the
brain and intestinal mucosa, HIV-1 may exhibit differential
evolution in the lungs and periphery. The latest efforts to
characterize the HIV-1 envelope gene in matched blood and
lung samples from 18 HIV-infected subjects suggest continu-
ous reseeding of viral forms between the peripheral blood
and lung tissues in most patients [36].
Histologically, HIV-infected patients do not differ from
uninfected counterparts with PAH; 80% of HIV-infected
patients also exhibit the concentric laminar intimal ﬁbrosis,
medial hypertrophy and plexiform lesions that are hallmarks
of PAH [14]. Additional landmarks include augmented
expression of smooth muscle cell/ﬁbroblast growth factors
such as platelet-derived growth factor.
Just as in severe PAH, macrophages, lymphocytes and den-
dritic cells are important inﬂammatory cellular components
in the perivasculature of HIV tissues. Hence, HIV-induced
chronic inﬂammation and immune hyperactivation may enrich
the proinﬂammatory milieu implicated in HIV-PAH.
HIV affects the dynamics of the endothelial cell (EC) micro-
environment
The endothelium is a dynamic entity that constantly communi-
cates with cellular components in blood and with the extra-
cellular matrix. Monocytes/macrophages migrate through the
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endothelium to ensure immune surveillance and replenishment
of myeloid cells.
Westhorpe et al. [37] showed that chronic exposure of
monocytes/macrophages to HIV signiﬁcantly decreased the
emigration of macrophages from tissues, by 67%. Their in vi-
tro system measured forward and reverse transmigration,
and suggested that HIV-infected macrophages are capable of
migration through the endothelium but not re-entry into the
bloodstream. These studies suggest that the presence of
‘trapped’ macrophages in tissues may result in defective
monocyte/macrophage-mediated immune responses, as well
as the establishment of tissue HIV reservoirs. The mecha-
nisms that account for this differential impairment in transen-
dothelial migration remain to be outlined.
There is no evidence that HIV infects the pulmonary vas-
cular endothelium, but HIV proteins are known to be nox-
ious to ECs; viral proteins and their interactions with
molecular partners in the infected host are strong candidates
for cause–effect relationships, because they may promote
apoptosis, growth and proliferation [38]. PAH has been
linked with viral proteins in infections with hepatitis B virus
and human herpes virus-8, although the latter is not statisti-
cally associated with PAH [2,39].
At least three of the HIV proteins are implicated in the
pathology of PAH. For example, HIV attaches and fuses
through the host cell membrane, thanks to the envelope gly-
coprotein-120 (gp-120) present on the surface of HIV viri-
ons. Cell-free HIV-1 gp-120, which has been detected in the
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blood, cerebrospinal ﬂuid and brains of HIV/AIDS patients,
stimulates proinﬂammatory cytokine production from mono-
cytes/macrophages [40], increases the secretion of endo-
thelin-1, and induces apoptosis of human lung ECs [41]. The
HIV protein Tat (transactivator of transcription) also acti-
vates ECs, and has angiogenic properties.
These HIV proteins may contribute to HIV cardiomyo-
pathy. Post-mortem studies in HIV patients with cardiomyo-
pathy showed that HIV infection was restricted to
inﬂammatory cells, but no virus was found in ECs or cardio-
myocytes. Extended observations in vitro demonstrated that
the HIV proteins gp-120 and Tat generated proapoptotic
signals that induced apoptosis in bystander cardiomyocytes
[42].
HIV transgenic murine models show that elevated proin-
ﬂammatory cytokines reduce sodium channel function, which
may lead to arrhythmias [43]. In addition, HIV gp-120 exerts
a negative inotropic effect in ventricular myocytes, via phos-
phorylation of p38 mitogen-activated protein kinase and tro-
ponin 1, upon binding to the CXCR4 receptor [44]. Finally,
expression of HIV Tat in the heart induces oxidative stress
[45]. HIV-induced cardiomyopathy is a recognized clinical
problem that remains to be investigated.
HIV-1 Nef co-localizes to ECs. Nef, originally thought to
be a negative factor, because it is dispensable for viral repli-
cation and cytopathicity in vitro, is expressed early during
viral infection and is a strategic player in HIV pathogenesis.
The association between Nef and obliterative PAH-like vas-
cular lesions in macaque lungs (similar to those in end-stage
human PAH) was demonstrated previously [46].
Furthermore, HIV-1 nef signature sequences were identi-
ﬁed in patients with HIV-PAH, as compared with counter-
parts without PAH (FASEB J 2009; Abstract 331.1). Nef
crosses cellular membranes and enters target cells via
chemokine receptors such as CXCR4. This receptor is
expressed on ECs, which may take up Nef as innocent
bystander cells. In addition, Nef complexes with several host
cell proteins, and recruits host adaptor proteins to comman-
deer trafﬁcking of intracellular vesicles participating in secre-
tory and endocytic pathways [47].
These studies support the concept that Nef perturbs the
subcellular environment.
On the Quest for Biomarkers and Early
Identiﬁcation
HIV evolutionary patterns in the lungs may be playing a role
in HIV-PAH. The high mutational proﬁle of HIV is the main
hurdle in the development of vaccines to prevent and/or
cure this infection. However, this feature of HIV may set the
stage for selection of speciﬁc HIV quasispecies at speciﬁc
anatomical sites such as the lung, where virus presence may
translate into a disease phenotype.
Research and clinical efforts should be driven by the
imperative to understand HIV-PAH, so that reliable thera-
peutic targets can be pinpointed. Itemization of established
risk factors playing strongest roles in HIV-PAH, as well as
additional views that merit consideration, reveals the com-
plexity of this disease (Fig. 2).
A wealth of data suggest that HIV-1 Nef is a broad-spec-
trum modulator that may impact on both infected and unin-
fected cells. The ﬁnding of nef signature sequences in
patients with HIV-PAH as compared with normotensives,
together with the tight sequence–function relationship intrin-
sic to Nef, offers the potential use of mutations in Nef as a
screening tool for HIV-PAH. Basic science techniques cou-
pled with bioinformatics approaches may redirect efforts to
understand the consequences of such mutations in HIV Nef
in the context of pulmonary vascular biology.
Conclusions
HIV-PAH is a severe manifestation in the course of HIV dis-
ease. The occurrence of dyspnoea in a patient with HIV infec-
tion that is unexplained after appropriate evaluation of
infectious causes should prompt further evaluation of PH, par-
ticularly if there is evidence of right ventricular dysfunction.
Clinicians should be aware that the appearance and rapid pro-
gression of shortness of breath and other cardiopulmonary
symptoms in HIV-infected individuals should suggest HIV-PAH.
A systematic cardiopulmonary evaluation and follow-up
should be incorporated in the clinical management of HIV-
infected patients. Furthermore, improved awareness should
lead to increased referral to specialized centres to initiate
speciﬁc management and therapies in order to enhance qual-
ity of life, exercise capacity, and survival.
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